World Pharma News / Published News

1
Vote

Novo Nordisk and Innate Pharma swap product rights

Posted by worldpharmanews 1 day 5 hours ago (http://www.worldpharmanews.com)
Category: Financial | Tags: novo nordisk innate pharma

Novo Nordisk A/S and Innate Pharma have reached an agreement by which Innate Pharma is granted development and commercialisation rights to NN1975/IPH 2101 in exchange for EUR 2.5 million upfront paym read more »
Discuss Add this link to... Bury

1
Vote

Bayer Reports Progress in Clinical Program for Riociguat

Posted by worldpharmanews 1 day 18 hours ago (http://www.worldpharmanews.com)
Category: Clinical Trials | Tags: bayer riociguat

Based on positive Phase II trial findings, Bayer Schering Pharma will move into Phase III trials with its oral agent riociguat (BAY 63-2521). Riociguat is the first member of a new class of vasodilat read more »
Discuss Add this link to... Bury

1
Vote

Philips develops ultrasound-activated microbubbles for localized delivery of cancer drugs

Posted by worldpharmanews 2 days ago (http://www.worldpharmanews.com)
Category: Research & Development | Tags: philips

Philips is developing an ultrasound-based drug delivery technology that is designed to increase the effectiveness and reduce the side effects of chemotherapy treatment for certain types of cancer. Th read more »
Discuss Add this link to... Bury

1
Vote

Pharmaceutical Forum Concluded Successfully

Posted by worldpharmanews 4 days ago (http://www.worldpharmanews.com)
Category: Research & Development | Tags: pharmaceutical forum

The final report of the Pharmaceutical Forum has been presented in Brussels setting out principles and recommendations on three key challenges in the pharmaceutical landscape. Firstly, how to improve read more »
Discuss Add this link to... Bury

2
Vote

Drug Injury Watch: New Warning About Dostinex Side Effect Fibrotic Cardiac Valvulopathy In U.K.

Posted by tjlpa 4 days ago (http://www.drug-injury.com)
Category: Blogs | Tags: dostinex drug-safety drug-injury

September 2008 Dear Doctor Letter From Pfizer Follows 2007 EMEA Safety Review Of Cabergoline read more »
Discuss Add this link to... Bury

1
Vote

Boehringer Ingelheim signs a license agreement with Evec Inc. for its fully-human antibody programme

Posted by worldpharmanews 5 days ago (http://www.worldpharmanews.com)
Category: Corporate | Tags: boehringer ingelheim evec

Boehringer Ingelheim has signed a licence agreement with Evec, Inc., Japan, for one of its fully-human therapeutic antibody programmes. Based on the agreement, Boehringer Ingelheim will obtain worldw read more »
Discuss Add this link to... Bury

2
Vote

Breaking Up Is Hard to Do: Pfizer to Cut Jobs and Refocus Research Efforts

Posted by cliffmz 6 days ago (http://www.biojobblog.com)
Category: Blogs | Tags: pharma layoffs downsizing

Pfizer announced that it will cut R&D jobs and abandon its research efforts in the areas of cardiovascular diseases, cholesterol management, osteoporosis, anemia and liver and muscle diseases. The co read more »
Discuss Add this link to... Bury

1
Vote

Roche invests 215 million Swiss francs in diagnostics facility at Penzberg

Posted by worldpharmanews 6 days ago (http://www.worldpharmanews.com)
Category: Financial | Tags: roche

Roche is investing 215 million Swiss francs (136 million euros) in research, development and production at its site in Penzberg, near Munich. The money will be used to construct a multi-purpose build read more »
Discuss Add this link to... Bury

2
Vote

Drug Injury Watch: FDA Alerts Doctors That Revlimid Can Cause Serious Skin Reactions In Patients

Posted by tjlpa 6 days ago (http://www.drug-injury.com)
Category: Blogs | Tags: revlimid fda drug-safety drug-injury

Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, And Erythema Multiforme Are Associated With Revlimid Use read more »
Discuss Add this link to... Bury

1
Vote

Shire Limited has changed its name to Shire plc

Posted by worldpharmanews 6 days ago (http://www.worldpharmanews.com)
Category: Corporate | Tags: shire

Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that following the approval by shareholders at the Annual General Meeting on September 24, 2008, the read more »
Discuss Add this link to... Bury